An economic model of Parkinson's disease: Implications for slowing progression in the United States

Movement Disorders

Volumn 28, Issue 3, 2013, Pages 319-326

  Johnson, Scott J ^a   Diener, Melissa D ^a   Kaltenboeck, Anna ^a   Birnbaum, Howard G ^a   Siderowf, Andrew D ^b  

^a ANALYSIS GROUP   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Benefit; Cost; Disease modification; Model; Parkinson's disease

Indexed keywords

ARTICLE; DEMENTIA; DISEASE COURSE; ECONOMIC EVALUATION; HEALTH CARE COST; HEALTH CARE UTILIZATION; HIDDEN MARKOV MODEL; HOEHN AND YAHR SCALE; HUMAN; MORTALITY; PARKINSON DISEASE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SYSTEMATIC REVIEW; UNITED STATES;

COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MARKOV CHAINS; MODELS, ECONOMETRIC; PARKINSON DISEASE; PROBABILITY; QUALITY OF LIFE; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TIME FACTORS; UNITED STATES;

EID: 84875486354     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25328     Document Type: Article

References (50)

1. Schenkman M, Zhu CW, Cutson TM, Whetten-Goldstein K. Longitudinal evaluation of economic and physical impact of Parkinson's disease. Parkinsonism Relat Disord. 2001;8:41-50.
2. Whetten-Goldstein K, Sloan F, Kulas E, Cutson T, Schenkman M. The burden of Parkinson's disease on society, family, and the individual. J Am Geriatr Soc. 1997;45:844-849.
3. Van Den Eeden SK, Tanner CM, Bernstein AL et al. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am J Epidemiol. 2003;157:1015-1022.
4. Huse DM, Schulman K, Orsini L, Castelli-Haley J, Kennedy S, Lenhart G. Burden of illness in Parkinson's disease. Mov Disord. 2005;20:1449-1454.
5. Noyes K, Liu H, Li Y, Holloway R, Dick AW. Economic burden associated with Parkinson's disease on elderly Medicare beneficiaries. Mov Disord. 2006;21:362-372.
6. Keränen T, Kaakkola S, Sotaniemi K, et al. Economic burden and quality of life impairment increase with severity of PD. Parkinsonism Relat Disord. 2003;9:163-168.
7. Kaltenboeck A, Johnson SJ, Davis MR, et al. Direct costs and survival of Medicare beneficiaries with early and advanced Parkinson's disease. Parkinsonism Relat Disord. 2012;18:321-326.
8. Spottke AE, Reuter M, Machat O, et al. Cost of illness and its predictors for Parkinson's disease in Germany. Pharmacoeconomics. 2005;23:817-836.
9. Hart RG, Pearce LA, Ravina BM, Yaltho TC, Marler JR. Neuroprotection trials in Parkinson's disease: systematic review. Mov Disord. 2009;24:647-654.
10. Bhatteram VA, Siddiqui O, Kapcala LP, Gobburu JV. Endpoints and analyses to discern disease-modifying drug effects in early Parkinson's disease. AAPS J. 2009;11:456-464.
11. Siebert U, Bornschein B, Walbert T, Dodel RC. Systematic assessment of decision models in Parkinson's disease. Value Health. 2004;7:610-626.
12. Shearer J, Green C, Counsell CE, Zajicek J. The use of decision-analytic models in Parkinson's disease: a systematic review and critical appraisal. Appl Health Econ Health Policy. 2011;9:243-258.
13. Poewe W. The natural history of Parkinson's disease. J Neurol. 2006;253(Suppl 7):VII/2-VII/6.
14. Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson's disease? J Neurol Neurosurg Psychiatry. 2000;69:308-312.
15. Claxton K, Posnett J. An economic approach to clinical trial design and research priority-setting. Health Econ. 1996;5:513-524.
16. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology. 1967;17:427-442.
17. Weinstein M. How much are Americans willing to pay for a quality-adjusted life year? Med Care. 2008;46:343-345.
18. Stinnett AA, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making. 1998;18(2 Suppl):S68-S80.
19. Johnson S, Davis M, Kaltenboeck A, et al. Early retirement and income loss in patients with early and advanced Parkinson's disease. Appl Health Econ Health Policy. 2011;9:367-376.
20. Shoulson I, Oakes D, Fahn S, et al. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol. 2002;51:604-612.
21. Muslimović D, Post B, Speelman JD, Schmand B. Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology. 2005;65:1239-1245.
22. Foltynie T, Brayne CEG, Robbins T, Barker RA. The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study. Brain. 2004;127:550-560.
23. Siderowf A, Ravina B, Glick HA. Preference-based quality-of-life in patients with Parkinson's disease. Neurology. 2002;59;103-108.
24. Fletcher P, Leake A, Marion MH. Patients with Parkinson's disease dementia stay in the hospital twice as long as those without dementia. Mov Disord. 2011;26:919.
25. Riedel O, Klotsche J, Spottke A, et al. Cognitive impairment in 873 patients with idiopathic Parkinson's disease: results from the German Study on Epidemiology of Parkinson's Disease with Dementia (GEPAD). J Neurol. 2008;255:255-264.
26. Aarsland D, Andersen K, Larsen JP, Lolk A, Nielsen H, Kragh-Sørensen P. Risk of dementia in Parkinson's disease: a community-based, prospective study. Neurology. 2001;56:730-736.
27. Giladi N, Treves TA, Paleacu D, et al. Risk factors for dementia, depression, and psychosis in long-standing Parkinson's disease. J Neural Transm. 2000;107:59-71.
28. Williams-Gray CH, Evans JR, Goris A, et al. The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain. 2009;132:2958-2969.
29. Vossius C, Larsen JP, Janvin C, Aarsland D. The economic impact of cognitive impairment in Parkinson's disease. Mov Disord. 2011;26:1541-1544.
30. Xu J, Kochanek KD, Tejada-Vera B. Deaths: preliminary data for 2007. National Vital Statistics Reports, Vol. 58, No. 1, August 19, 2009. Available at: http://www.cdc.gov/nchs/data/nvsr/nvsr58/nvsr58_01.pdf. Accessed on December 7, 2012.
31. Diem-Zangerl A, Seppi K, Wenning GK, et al. Mortality in Parkinson's disease: a 20-year follow-up study. Mov Disord. 2009;24:819-825.
32. Liou HH, Wu CY, Chiu YH, et al. Natural history and effectiveness of early detection of Parkinson's disease: results from two community-based programmes in Taiwan (KCIS no. 11). J Eval Clin Pract. 2008;14:198-202.
33. Diamond SG, Markham CH, Hoehn MM, McDowell FH, Muenter MD. An examination of male-female differences in progression and mortality of Parkinson's disease. Neurology. 1990;40:763-766.
34. Lees AJ, Katzenschlager R, Head J, Ben-Shlomo Y. Ten-year follow-up of three different initial treatments in de-novo PD: a randomized trial. Neurology. 2001;57:1687-1694.
35. Hely MA, Morris JGL, Traficante R, Reid WG, O'Sullivan D, Williamson P. The Sydney multicentre study of Parkinson's disease: progression and mortality at 10 years. J Neurol Neurosurg Psychiatry. 1999;67:300-307.
36. Zhao YJ, Wee HL, Chan YH, et al. Progression of Parkinson's disease as evaluated by Hoehn and Yahr stage transition times. Mov Disord. 2010;25:710-716.
37. Di Rocco A, Molinari SP, Kollmeier B, Yahr MD. Parkinson's disease: progression and mortality in the L-DOPA era. Adv Neurol. 1996;69:3-11.
38. Müller J, Wenning GK, Jellinger K, McKee A, Poewe W, Litvan I. Progression of Hoehn and Yahr stages in parkinsonian disorders: a clinicopathologic study. Neurology. 2000;55:888-891.
39. Hoehn MM. Parkinsonism treated with levodopa: progression and mortality. J Neural Transm Suppl. 1983;19:253-264.
40. Rajput AH, Voll A, Rajput ML, Robinson CA, Rajput A. Course in Parkinson disease subtypes: a 39-year clinicopathologic study. Neurology. 2009;73:206-212.
41. Sato K, Hatano T, Yamashiro K, et al. Prognosis of Parkinson's disease: time to stage III, IV, V, and to motor fluctuations. Mov Disord. 2006;21:1384-1395.
42. Alves G, Wentzel-Larsen T, Aarsland D, Larsen JP. Progression of motor impairment and disability in Parkinson disease: a population-based study. Neurology. 2005;65:1436-1441.
43. The NINDS NET-PD Investigators. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson's disease. Neurology. 2007;68:20-28.
44. Losina E, Walensky RP, Kessler CL, et al. Cost-effectiveness of total knee arthroplasty in the United States: patient risk and hospital volume. Arch Intern Med. 2009;169:1113-1121.
45. Tosteson A, Stout NK, Fryback DG, et al. Cost-effectiveness of digital mammography breast cancer screening. Ann Intern Med. 2008;148:1-10.
46. Freeman JV, Zhu RP, Owens DK, et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Int Med. 2011;154:1-11.
47. Cohn DE, Kim KH, Resnick KE, O'Malley DM, Straughn JM. At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis. J Clin Oncol. 2011;29:1247-1251.
48. Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA. 2003;290:228-237.
49. Weintraub D, Moberg PJ, Duda JE, Katz IR, Stern MB. Effect of psychiatric and other nonmotor symptoms on disability in Parkinson's disease. J Am Geriatr Soc. 2004;52:784-788.
50. Chaudhuri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol. 2006;5:235-245.